Profound Medical Corp
Company Profile
Business description
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Contact
2400 Skymark Avenue
Unit 6
MississaugaONL4W 5K5
CANT: +1 647 476-1350
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
162
Stocks News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
stocks
ASX top pick remains cheap with narrowing brand focus
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,804.60 | 39.10 | 0.45% |
| CAC 40 | 8,161.83 | 41.60 | -0.51% |
| DAX 40 | 24,195.31 | 237.75 | -0.97% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,254.81 | 27.48 | 0.27% |
| HKSE | 24,110.29 | 297.67 | -1.22% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 63,239.52 | 939.75 | -1.46% |
| NZX 50 Index | 13,181.08 | 72.57 | -0.55% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,608.60 | 45.10 | 0.53% |
| SSE Composite Index | 3,974.90 | 18.33 | -0.46% |